title: Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
abstract: Amphotericin B deoxycholate (AmBd) has been a standard therapy for IFI but is associated with high adverse event and mortality rates. A retrospective review was undertaken to describe adverse events and clinical outcomes in adult patients with IFI treated with only AmBd as initial therapy.
authors.affiliation: Division of Infectious Diseases, University Hospitals of Geneva, Switzerland. jorge.garbino@hcuge.ch
authors.forename: Jorge
authors.initials: J
authors.lastname: Garbino
authors.forename: Lydia
authors.initials: L
authors.lastname: Markham
authors.forename: Raimonda
authors.initials: R
authors.lastname: Matulionyte
authors.forename: Vincent
authors.initials: V
authors.lastname: Rives
authors.forename: Daniel
authors.initials: D
authors.lastname: Lew
mesh_terms: D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003840:Deoxycholic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006760:Hospitalization; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination